INOVIO PHARMACEUTICALS INC

For the period ended Dec 31, 2023. Filed Mar 6, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 6, 2024

INO$1.51+24.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	For the Year ended December 31,
	2023	2022	2021
Revenue from collaborative arrangements and other contracts, including affiliated entity	$832,010	$10,262,268	$1,774,758
Operating expenses:
Research and development	86,676,563	187,650,503	249,240,324
General and administrative	47,582,104	90,185,285	53,752,353
Impairment of goodwill	10,513,371	—	—
Total operating expenses	144,772,038	277,835,788	302,992,677
Loss from operations	(143,940,028)	(267,573,520)	(301,217,919)
Other income (expense):
Interest income	8,133,290	4,782,030	3,363,080
Interest expense	(1,222,789)	(1,253,952)	(1,936,447)
Gain (loss) on investment in affiliated entity	773,145	(1,899,654)	(553,570)
Net unrealized gain (loss) on available-for-sale equity securities	5,850,626	(7,846,172)	(3,222,838)
Other (expense) income, net	(4,711,596)	(3,861,584)	343,371
Net loss before share in net loss of Geneos	(135,117,352)	(277,652,852)	(303,224,323)
Share in net loss of Geneos	—	(2,165,213)	(434,387)
Net loss	$(135,117,352)	$(279,818,065)	$(303,658,710)
Net loss per share
Basic and diluted (1)	$(6.09)	$(14.07)	$(17.45)
Weighted average number of common shares outstanding
Basic and diluted (1)	22,173,662	19,885,182	17,402,483

(1) Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.